Canaglifozin Approved for Type 2 Diabetes
By: Kate Traynor
American Society of Health System Phamracists - www.ashp.org
BETHESDA, MD 01 April 2013— FDA and Janssen Pharmaceuticals Inc. (PDF) on March 29 announced the approval of canaglifozin for the treatment of type 2 diabetes mellitus in adults.
Canaglifozin, a once-daily oral therapy, should be used in conjunction with diet and exercise to improve glucose control in patients with type 2 diabetes.
The drug is not recommended for use in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. Canaglifozin is contraindicated in patients undergoing dialysis and those with severe kidney impairment or end-stage renal disease.
According to FDA, canaglifozin is a sodium–glucose cotransporter 2 inhibitor and the first drug in this class to be approved by the agency.
The for canaglifozin states that it inhibits glucose reabsorption by the kidney, resulting in increased urinary excretion of glucose.
Canaglifozin has been studied as a stand-alone therapy and in combination with metformin, sulfonylurea, metformin and sulfonylurea, and metformin and a thiazolidinedione, as well as in combination with insulin with or without other antihyperglycemic agents.
In clinical trials, canaglifozin improved hemoglobin A1c levels and fasting and postprandial blood glucose levels and was associated with weight loss in patients with type 2 diabetes.
To read the full article please go to: http://www.ashp.org/menu/News/PharmacyNews/NewsArticle.aspx?id=3883